



TO

All Providers, HMOs and Other Managed Care Programs

REGARDING

COVID-19 Vaccines Approved for Members Aged 6 Months to 5 Years

COVID-19 Vaccines Approved for Members Aged 6 Months to 5 Years

Effective for dates of service on and after June 17, 2022, ForwardHealth will reimburse providers for the administration of the Moderna and Pfizer COVID-19 vaccines to members aged 6 months to 5 years, following guidance and recommendations by the U.S. Food and Drug Administration, Centers for Disease Control and Prevention, and Centers for Medicare & Medicaid Services.

When administering a vaccine to children under the age of 6, pharmacists must comply with Wis. Stat. § [450.035\(2c\)](#), which has provisions allowing trained pharmacists to administer vaccines to persons aged 6 years and younger. Providers are reminded that Moderna COVID-19 vaccines are not yet approved for members aged 6 through 17.

Refer to ForwardHealth Updates [2021-01](#), titled “COVID-19 Vaccine Billing and Reimbursement,” and [2021-09](#), titled “COVID-19 Vaccine Policy and Coverage Clarifications,” for more information.

MODERNA PROCEDURE CODE	DESCRIPTION
91311	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use
0111A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose
0112A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose

PFIZER PROCEDURE CODE	DESCRIPTION
91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
0081A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose
0082A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose

Additional information is available on the federal [Advisory Committee on Immunization Practices webpage](#) and the [Wisconsin Department of Health Services COVID-19 webpage](#).

COVID-19-related ForwardHealth Alerts and Updates are available on the [COVID-19: ForwardHealth News and Resources](#) page of the ForwardHealth Portal.